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Extrapulmonary small cell carcinoma occurs in nearly all organs except the central nervous system and the liver. We are presenting
a case of renal small cell carcinoma (SCC) with two unique characters. A 75-year-old patient was evaluated for back pain with
no other complaints. Magnetic Resonance (MR) imaging of the abdomen revealed homogeneous tumor in the left renal pelvis
extending beyond the kidney. Metastatic workup was negative. A left nephroureterectomy was performed. Histopathology and
immunohistochemistry revealed a small cell carcinoma of the renal pelvis. The patient declined adjuvant therapy and died 2
months after surgery due to unrelated causes. After comprehensive worldwide literature search, we found 13 cases of SCC of the
renal pelvis, including the current case. The mean age was 61.6 years (37–83), with a M:F ratio of 1:1.8. The average duration of
symptoms was 71.4 days (21–168). Gross hematuria was the most common symptom (69.2%) followed by pain (61.5%). Adjuvant
chemotherapy was provided to 4 patients (30.7%), and neoadjuvant to 1 patient. The median survival of patients who did and
did not receive chemotherapy was 5.5 months (3–8) and 6 months (2–31), respectively, P<. 50. In conclusion, renal SCC (both
parenchymal and pelvic SCC) is a rapidly fatal disease with a median survival of ≤8m o n t h s .
1.Introduction
Extrapulmonary small cell carcinoma (EPSCC) is rare, and
comprises only 2.5% of all small cell carcinomas [1]. Nearly
1,000 cases of EPSCC are diagnosed every year in the United
States, which accounts for 0.1 to 0.4% of all malignancies
[1]. EPSCC has been reported in nearly all organs except
the central nervous system and the liver, with the most
common site for EPSCC being the urinary bladder [1, 2].
Primary renal small cell carcinoma (SCC) are rare, and
to date, approximately 50 cases have been reported in the
world literature [3]. Renal SCC may occur in either the
renal pelvis or the renal parenchyma. SCC occurring in
the renal pelvis have a distinct feature in that they occur
in association with nonneuroendocrine components like
TCC, adenocarcinoma, squamous cell carcinoma, and rarely
carcinoid [4]. In this report, we present a case of SCC of the
renal pelvis with a pertinent review of the literature.
2.CaseReport
A 75-year-old male presented with lower back pain for 2
weeks, not responding to nonsteroidal anti-inﬂammatory
drugs (NSAIDs). He denied trauma to the back and had
noneurologicchanges,hematuria,orabdominalcomplaints.
He had similar pain 1 year prior which was relieved by
NSAIDs. Physical examination revealed no abnormalities.
Laboratoryevaluationwasremarkableforabloodureanitro-
gen of 78.8mg/dL and a creatinine of 2.8mg/dL. Ultrasound
examination of the abdomen was unremarkable. Magnetic
resonance imaging of the abdomen and pelvis identiﬁed a
4.8 × 4 × 3.7cm lobulated, homogeneous tumor in the
left renal pelvis extending into the upper ureter and psoas
muscle. The tumor mass was isointense to skeletal muscle
on T1-weighted images and mildly hyperintense on T2-
weighted images with mild homogeneous contrast enhance-
ment (Figure 1). Preaortic, para-aortic, aortocaval, and2 ISRN Urology
Figure 1: Gadolinium-enhanced T1 Magnetic Resonance (MR)
image of small cell carcinoma of the left renal pelvis. The tumor
demonstrates mild homogeneous contrast enhancement (White
arrow).
retrocaval lymph nodes were enlarged. Metastatic workup
w a sn e g a t i v e .Al e f tn e p h r o u r e t e r e c t o m yw a sp e r f o r m e d .
Intraoperatively, a large polypoidal growth arising from the
left renal pelvis with multiple tumor foci in the calyceal
system was noted. The tumor extended into the perirenal
fat and Gerota’s fascia. Multiple hard, irregular lymph nodes
measuring ∼ 2 × 2cm were noted in the left hilar, preaortic,
and para-aortic regions; the lymph nodes were ﬁxed to the
aorta. A formal lymph node dissection was performed and
lymph nodes close to the aorta were injected with absolute
alcohol. There was no evidence of left renal vein invasion.
Histopathology revealed a small cell carcinoma with
monomorphic tumor cells containing scanty cytoplasm
and dispersed chromatin. Nuclei were hyperchromatic with
nuclear moulding and inconspicuous nucleoli. Mitosis was
prominent. There was no evidence of nonneuroendocrine
component. Tumor emboli were seen in the renal artery
and in the lymphatic vessels. The tumor inﬁltrated into the
wall of the ureter. The tumor cells showed immunoreactiv-
ity for neuron-speciﬁc enolase (NSE) and chromogranin.
4/4lymph nodes were positive for metastases. Adjuvant
chemotherapy and radiotherapy were considered, but the
patient declined additional therapy and died 2 months later
due to unrelated causes.
3.MaterialsandMethods
A comprehensive English and non-English search for all arti-
cles pertinent to small cell carcinoma of the renal pelvis was
conducted using PubMed, a search engine provided by the
U.S.NationalLibraryofMedicineandtheNationalInstitutes
of Health. Key words searched included: extrapulmonary
small cell carcinoma, small cell carcinoma of the kidney,
and small cell carcinoma of the renal pelvis. Cases identiﬁed
were analyzed in regard to age and gender of the patients,
duration of symptoms, preoperative investigations including
immunohistochemical and ultrastructural studies, tumor
size, treatment, and outcome. Patients were staged utilizing
a two-stage system. Limited disease was deﬁned as tumor
localized to the organ of origin and/or locoregional lymph
nodes that were easily encompassed within one radiation
therapy (RT) treatment portal. Any evidence of disease
beyond that was classiﬁed as extensive disease [15]. Collected
data was tabulated and calculations were performed using
Microsoft Excel statistical functions.
4. Results
Thirteen cases of small cell carcinoma of the renal pelvis,
including the current case, have been reported in the world
literature (Table 1). Two case reports from China with
English language abstract are included (cases 8 and 9), while
one case report from France without an abstract in English
language is excluded from this review [16]. The mean age at
d i a g n o s i sw a s6 1 . 6y e a r s( 3 7t o8 3y e a r s ) ,w i t haM:Fr a t i o
of 1:1.8. History of tobacco smoking was available in four
patients of whom three smoked. The average duration of
symptoms was 71.4 days (21 to 168 days). Gross hematuria
was the most common symptom (69.2%) followed by pain
(61.5%). One patient presented with asthenia, anorexia, and
abdominal discomfort. No patient had an abdominal mass
at presentation. Urine cytology was done in 2 cases (cases
7 and 11) and was reported as transitional cell carcinoma
(TCC) in both. A Contrast-enhanced computed tomography
(CECT) was the most commonly performed investigation
(61.5%)followedbyintravenouspyelographyandretrograde
pyelography (30.8%). Preoperative biopsy was done in only
one patient (7.7%), and it was reported as SCC. Two cases,
(15.4%) including the present case, had locally advanced
disease and lymph node metastases. No patient had systemic
metastases or paraneoplastic symptoms at presentation.
Histopathology results including local spread and lymph
node metastasis were available for 10 cases. The mean and
median tumor size was 6.3 and 5cm, with two patients hav-
ing tumor extension beyond the kidney into lymph nodes.
A nonneuroendocrine component was present in 11 of 13
(84.6%) patients. In one case (case 8), the histopathological
ﬁndings were not clearly reported. Transitional cell carci-
noma (TCC) was the most common nonneuroendocrine
component (61.5%); one patient had squamous and glandu-
lar components and another had squamous cell component
with sarcomatoid diﬀerentiation. Ultrastructural ﬁndings
were mentioned in 4 of 13 (30.8%) patients, and among
these patients membrane bound neurosecretory granules
were found in 3 patients and desmosomes in 2 patients. The
immunohistochemical staining methods were inconsistent,
except for the use of chromogranin and neuron-speciﬁc
enolase (NSE) (Table 2). NSE staining was used in all except
one case (case 10), and chromogranin staining was used in
all except two cases (case 6 and 11).
Surgery was performed in all cases. Seven patients
(53.8%) had a nephrectomy, while six patients (46.1%) had
a nephroureterectomy. Two of the 13 patients (cases 5 and
10) had radical surgery. All patients but two had limited
stage disease; adequate information to stage the tumor
was not available for two patients. Adjuvant chemotherapy
was provided to four patients (30.7%), and neoadjuvantISRN Urology 3
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Table 2: Summary of immunohistochemical staining for all published reports of patients with small cell carcinoma of the renal pelvis.
Histochemical stains Patients
1 2 3 4 5 6 7 8 9 10 11 12 Current patient
Chromogranin −− − +, s − +++ / −,f + +
Cytokeratin + + +
CEA − ++
EAB 902 and 903 +
Epithelial markers − ++ − +/−,f
LEU-5 (CD2) − +
N S E + ,d ,s + ,d ,s − +, s − +++ + + +
Synaptophysin +,d, s − + + ,s + + ,d ,s +
S100 α +/−
Vimentin − +
−: negative, +: positive, +/−: inconclusive, f: focal, d: diﬀuse, s: strong, CEA carcino embryonic antigen, EAB 902 and 903: monoclonal antikeratin antibodies,
LEU-5(CD2): enkephalin, NSE: neuron-speciﬁc enolase, and S 100α: protein.
chemotherapy was given to 1 patient. Palliative radiotherapy
was used in one patient for local recurrence and scalp
metastases.Sixpatients(46.1%)developedmetastasisduring
followup, with lung being the most common site of relapse
(50%) followed by local recurrence, lymph nodes, and
the liver (33.3%). Nine patients (69.2%) died of disease
(DOD). The median survival of patients who did not receive
chemotherapy (5 of 9 patients) was 6 months (2 to 31
months).Thosewhoreceivedchemotherapy(4of9patients)
had a median survival of 5.5 months (3 to 8 months). Two
patients remained alive and disease free at 16 (case 2) and
11 months (case 11). The current patient died of unrelated
causes at 2 months and follow-up was not mentioned in one
case (case 12).
5. Discussion
The classiﬁcation of pulmonary or extrapulmonary small
cell carcinoma is based upon histological diagnosis of SCC
with a normal chest X-ray, CT scan of the chest and sputum
cytology [15] .T h eﬁ r s tc a s eo fp r i m a r yr e n a ls m a l lc e l l
carcinoma (SCC) was reported by Capella et al. in 1984.
Since then, aproximately 50 cases of renal SCC (including
13 cases of small cell carcinoma of the renal pelvis) have
been described. Small cell carcinoma arising from the renal
pelvismaybediﬀerentiatedfromthatoriginatingintherenal
parenchyma by the presence of nonneuroendocrine compo-
nents, tumor inﬁltration of the transitional cell epithelium
of the renal pelvis and strong positive staining for neuron-
speciﬁc enolase [7, 10]. As compared to prior reports, the
current case had two unique characteristics; the absence of
nonneuroendocrinecomponentandthepresenceofmultiple
tumors [14].
Small cell carcinoma (SCC) of renal pelvis is a rare
tumor, usually seen in the sixth decade of life with slight
female preponderance (62.5%). Smoking is a risk factor
for EPSCC, particularly for SCC of the head and neck
and esophagus. In this review, only 23% of patients had a
history of smoking, but smoking history was not uniformly
reported. Galanis et al. reported a history of smoking in 63%
of patients with EPSCC [15]. Gross hematuria was the most
common mode of presentation (69.2%), and no patients had
paraneoplastic manifestations. Ectopic adrenocorticotrophic
hormone (ACTH) production, syndrome of inappropriate
antidiuretic hormone (SIADH) production and hypophos-
phatemia, has been reported in isolated patients with SCC
of the urinary bladder and prostate [6]. Magnetic resonance
(MR) imaging of SCC of the kidney typically demonstrates
diminishedsignalonT1-weightedimagesandheterogeneous
mixed signal on T2-weighted images, whereas renal cell
carcinoma (RCC) typically appears as an irregular mass
with ill-deﬁned margins that arises from the renal cortex,
and is slightly hypointense on T1-weighted images and
slightly hyperintense on T2-weighted images relative to renal
cortex. Large (>5cm), hypervascular RCC most commonly
demonstrate central necrosis [17]. Lack of central necrosis
and a predominantly medullary location of a tumor should
raise the suspicion of another histologic entity. Though
not typically done for RCC biopsy should be considered
for renal tumors with atypical radiological ﬁndings. The
diagnosis of renal SCC is based on light microscopic criteria
established for the diagnosis of pulmonary SCC. Ultrastruc-
tural and immunohistochemical studies may be required to
diﬀerentiate renal SCC from lymphoma, carcinoid tumor,
neuroblastoma,reninsecretingtumors,primitiveneuroecto-
dermaltumor/Ewingsarcoma,andrhabdomyosarcoma[18].
A diagnostic algorithm is presented in Figure 2 to diﬀeren-
tiate small cell carcinoma from similar appearing tumors.
Light microscopy reveals small and oval spindle-shaped cells
measuring up to twice the diameter of normal lymphocytes,
inconspicuous nucleoli, Azzopardi phenomenon, nuclear
moulding, hyperchromatic, scant cytoplasm, and increased
mitotic activity (>11/10hpf). On electron microscopy, the
presence of membrane bound neurosecretory granules and
desmosomes is more consistent with SCC [19]. Neuron-
speciﬁc enolase (NSE), chromogranin, and synaptophysin
are the most commonly used neuroendocrine markers in the
evaluation of renal SCC. Synaptophysin staining is speciﬁc6 ISRN Urology
Renal mass
Atypical radiological ﬁndings
not suggestive of RCC
Fine needle aspiration
biopsy
AE1/AE3 staining Carcinoma
Adenocarcinoma RCC
Neuroendocrine
tumor
Carcinoid tumor
PNET/Ewing sarcoma Lymphoma Rhabdomyosarcoma Neuroblastoma Rennin secreting
tumor
EMA +ve CD10 −ve
−ve
−ve
n
S100 +ve
CD99 +ve
CEA
cytokerati
MR imaging-kidney
Tumors > 5cm
Predominate medullary location
No central necrosis
Chest X-ray −ve
sputum cytology −ve
bronchoscopy −ve
CECT chest −ve
CD56, chromogranin, and
synaptophysin staining
Cytokeratin+
chromogranin+
synaptophysin+
CD56+
NSE+
Somatostatin+
seritonin+
calcitonin+
chromogranin+
NSE+
Vimentin+
CD45+
CD20+
LCA+
CD56−
Desmin+
myogenin+
MyoD1+
vimentin+
EMA+
NSE+
neuroﬁlament protein+
chromogranin+
synaptophysin+
VIP+
CD56+
Rennin+
actin+
vimentin+
CD34+
RCC: renal cell carcinoma, CECT: c :c ontrast enhanced computed tomography, AE1/AE3: pan-cytokeratin antibody, CD10: ommon acute
lymphocytic leukemia antigen, EMA: epithelial membrane antigen, CD56: neural cell adhesion molecule, NSE: neuron speciﬁc enolase,
S100: protein, CD99: single-chain type-1glycoprotein, CEA: carcinoebryonic antigen, CD45: single chain transmembraneous glycoprotein,
CD20: non-glycosylated phosphoprotein expressed on the surface of all mature B-cells, LCA: leucocyte common antigen,MyoD1: nuclear
phosphoprotein which induces myogenesis through transcriptional activation of muscle-speciﬁc genes, NSE: neuron speciﬁc enolase,
VIP: vasoactive intestinal peptide, CD34: cell surface glycoprotein and functions as a cell-cell adhesion factor.
Figure 2: Diagnostic algorithm for renal mass with atypical radiological ﬁndings.
for neuroendocrine cells as nonneuroendocrine components
may stain positive for NSE [6]. Kitamura et al. have reported
that NSE staining helps in identiﬁcation of neuroendocrine
cells and endocrine tumors independent of the hormones
or neurotransmitters produced [10]. Peri-nuclear crescent
and dot-like pattern of immunostaining for cytokeratin is
characteristicallyfoundinneuroendocrinecarcinoma,where
as it is less well expressed in primitive neuroectodermal
tumors [19].
Due to the rarity of renal SCC, deﬁnitive treatment
protocolsarelacking.However,availableinformationsuggest
that survival following surgery for renal SCC is poor,
and consideration of neoadjuvant chemotherapy may be
warranted [3]. Renal pelvis SCC is an aggressive tumor with
a median survival of 8.2 months. There is high incidence of
relapse (46.1%) even with limited stage disease. A similar
high incidence of relapse has been reported by Majhail et al.
(60%) and Galanis et al. (75%) among patients with renal
SCC and extrapulmonary SCC, respectively [3, 15]. A signif-
icantimprovementinoverallsurvivalhasbeenreportedwith
the use of platinum-based chemotherapy (20-month versus
8-month, P = .02) for cases of renal SCC [3]. In addition,
favorable outcomes have also been seen with cisplatin-based
chemotherapyforsmallcellcarcinomaarisingfromnonrenal
genitourinary and other extrapulmonary sites [3]. Galanis
et al. observed a 72% response rate in 22 patients with
extrapulmonary small cell carcinoma treated with platinum-
based regimens [15]. Regimens containing doxorubicin hadISRN Urology 7
a 57% response rate with a median duration of response
of only 4.5 months. Lo et al. reported an overall response
rate of 69% to combination chemotherapy with cisplatin
and etoposide in 13 patients with extrapulmonary small cell
carcinoma [20].
Several prognosis indicators have been identiﬁed for
SCC of the urinary tract. Chuang et al. have reported that
immunoreactivity with vimentin indicates poor prognosis
and development of early metastases [12]. Similarly, Goslin
et al. have reported that immunoreactivity with CEA carries
an unfavorable prognosis [21]. On multivariate analysis,
age of the patient >65yrs, high TNM staging, presence of
TCCcomponent,andmetastaticdiseaseatpresentationwere
predictive of poor survival [3, 15, 22].
6. Conclusion
Renal SCC (both parenchymal and pelvic SCC) has a rapidly
fatalcoursewithamediansurvivalof8months.Thereishigh
incidence of postoperative relapse (46.1 to 60%), probably
due to presence of occult metastasis at initial presentation.
The role of surgery in managing renal SCC is not clear
and neoadjuvant platinum-based chemotherapy may alter
survival rates. Renal biopsy should be considered for large
size (>5cm) medullary tumors with central necrosis.
References
[1] S. C. Remick and J. C. Ruckdeschel, “Extrapulmonary and
pulmonary small-cell carcinoma: tumor biology, therapy, and
outcome,” Medical and Pediatric Oncology,v o l .2 0 ,n o .2 ,p p .
89–99, 1992.
[2] K.Haider,R.K.Shahid,D.Finchetal.,“Extrapulmonarysmall
cell cancer: a Canadian province’s experience,” Cancer, vol.
107, no. 9, pp. 2262–2269, 2006.
[3] N. S. Majhail, P. Elson, and R. M. Bukowski, “Therapy and
outcome of small cell carcinoma of the kidney: report of two
cases and a systematic review of the literature,” Cancer, vol. 97,
no. 6, pp. 1436–1441, 2003.
[4] R. S. La, B. Bernasconi, D. Micello, G. Finzi, and C. Capella,
“Primary small cell neuroendocrine carcinoma of the kidney:
morphological, immunohistochemical, ultrastructural, and
cytogenetic study of a case and review of the literature,”
Endocrine Pathology, vol. 20, no. 1, pp. 24–34, 2009.
[ 5 ]S .E .M i l l s ,J .T .W o l f e ,a n dM .A .W e i s s ,“ S m a l lc e l l
undiﬀerentiated carcinoma of the urinary bladder: a light-
microscopic, immunocytochemical, and ultrastructural study
of12cases,”AmericanJournalofSurgicalPathology,vol.11,no.
8, pp. 606–617, 1987.
[6] H. Essenfeld, J. C. Manivel, P. Benedetto, and J. Albores-
Saavedra, “Small cell carcinoma of the renal pelvis: a clinico-
pathological, morphological and immunohistochemical study
of 2 cases,” Journal of Urology, vol. 144, no. 2, part 1, pp. 344–
347, 1990.
[7] L. Guillou, B. Duvoisin, C. Chobaz, G. Chapuis, and J. Costa,
“Combined small-cell and transitional cell carcinoma of the
renal pelvis: a light microscopic, immunohistochemical, and
ultrastructural study of a case with literature review,” Archives
of Pathology and Laboratory Medicine, vol. 117, no. 3, pp. 239–
243, 1993.
[8] L. Mazzucchelli, U. E. Studer, and R. Kraft, “Small-cell
undiﬀerentiated carcinoma of the renal pelvis 26 years after
subdiaphragmatic irradiation for non-Hodgkin’s lymphoma,”
British Journal of Urology, vol. 76, no. 3, pp. 403–404, 1995.
[9] I. Kuromatsu, N. Hayashi, M. Yanagawa, H. Tochigi, and
J. Kawamura, “Combined small cell and transitional cell
carcinoma of renal pelvis: a case report,” Hinyokika Kiyo, vol.
41, no. 1, pp. 47–50, 1995.
[10] M. Kitamura, T. Miyanaga, M. Hamada, Y. Nakata, Y. Satoh,
and T. Terakawa, “Small cell carcinoma of the kidney: case
report,” International Journal of Urology, vol. 4, no. 4, pp. 422–
424, 1997.
[11] S. Kojima, M. Mine, and H. Sekine, “Small cell carcinoma of
the kidney. A case report,” Nippon Hinyokika Gakkai Zasshi,
vol. 89, no. 6, pp. 614–617, 1998.
[12] C. K. Chuang and S. K. Liao, “A retrospective immuno-
histochemical and clinicopathological study of small cell
carcinomas of the urinary tract,” Chang Gung Medical Journal,
vol. 26, no. 1, pp. 26–33, 2003.
[13] N. Shimasaki, K. Inoue, H. Nishigawa, N. Kuroda, and T.
Shuin, “Combined small cell carcinoma and sarcomatoid
squamous cell carcinoma in the renal pelvis,” International
Journal of Urology, vol. 12, no. 7, pp. 686–689, 2005.
[14] J. Banerji, A. Korula, and J. Panicker, “Multicentric small
cell neuroendocrine neoplasm of the renal pelvis and ureter
withconcomitantfocalhigh-gradeurothelialcarcinomaofthe
ureter: a case report,” Indian Journal of Urology, vol. 24, no. 4,
pp. 571–574, 2008.
[15] E. Galanis, S. Frytak, and R. V. Lloyd, “Extrapulmonary small
cell carcinoma,” Cancer, vol. 79, no. 9, pp. 1729–1736, 1997.
[16] L. Senecal, “Undiﬀerentiated small cell carcinoma of the renal
pelvis with massive invasion of the kidney,” Union Med Can,
vol. 114, no. 2, p. 147, 1985.
[17] R. C. Semelka, Abdominal-Pelvic MRI. Kidneys, Wiley-Liss,
New York, NY, USA, 1st edition, 2002.
[ 1 8 ]B .K .A k k a y a ,U .M u s t a f a ,O .E s i n ,K .T u r k e r ,a n dK .
Gulten, “Primary small cell carcinoma of the kidney,” Urologic
Oncology, vol. 21, no. 1, pp. 11–13, 2003.
[19] K. G. Morgan, S. S. Banerjee, B. P. Eyden, and R. J. Barnard,
“Primary small cell neuroendocrine carcinoma of the kidney,”
Ultrastructural Pathology, vol. 20, no. 2, pp. 141–144, 1996.
[20] R. G. Lo, V. Canzonieri, A. Veronesi et al., “Extrapulmonary
small cell carcinoma: a single-institution experience and
review of the literature,” Annals of Oncology, vol. 5, no. 10, pp.
909–913, 1994.
[21] R. H. Goslin, A. T. Skarin, and N. Zamcheck, “Carcinoembry-
onic antigen. A useful monitor of therapy of small cell lung
cancer,” Journal of the American Medical Association, vol. 246,
no. 19, pp. 2173–2176, 1981.
[22] A. Ouzzane, T. P. Ghoneim, K. Udo et al., “Small cell
carcinoma of the upper urinary tract (UUT-SCC): report of
a rare entity and systematic review of the literature,” Cancer
Treatment Reviews. In press.